文献速递胰腺与胆道疾病消化道肿瘤与早癌

蛋白质生物标志物与替代甲基化游离DNA检测早期胰腺癌

Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.
PubMed 文献 · Gut · 2024-03-07

本研究在426例患者中评估血浆标志物对胰腺导管腺癌(PDAC)的鉴别能力,以CA19-9为锚定标志物,联合检测TIMP1、LRG1两种蛋白标志物及9个位点(涵盖61个CpG位点)的游离DNA胰腺特异性甲基化。在86例早期PDAC与86例匹配健康对照的测试集中,CA19-9的AUC为0.88,加入TIMP1、LRG1或9位点cfDNA甲基化标志物后AUC均升至0.92。在40例早期PDAC与40例匹配健康对照的验证集中,CA19-9、TIMP1与9位点cfDNA甲基化组合面板的AUC为0.86,高于CA19-9单用的0.82。

要点

  • 在86例早期PDAC与86例匹配健康对照中,CA19-9的AUC为0.88(95%CI 0.83-0.94)。
  • 加入TIMP1、LRG1或9位点cfDNA甲基化标志物后AUC均升至0.92。
  • 验证集中CA19-9+TIMP1+9位点cfDNA甲基化面板AUC为0.86,高于CA19-9单用的0.82。

核心结论

  • 包含蛋白质与甲基化cfDNA的循环标志物组合面板,相比CA19-9单用,提高了对早期PDAC的鉴别能力。

研究设计与样本

  • 研究在训练、测试和验证患者队列(总计n=426例患者)中评估循环标志物的鉴别能力,测量PDAC病例及慢性胰腺炎、结直肠癌(CRC)患者和健康对照的血浆标志物。
  • 以CA19-9为锚定标志物,检测两种蛋白标志物(TIMP1、LRG1)及9个位点(涵盖61个CpG位点)的cfDNA胰腺特异性甲基化。
  • 训练集n=124例患者,测试集为86例早期PDAC与86例匹配健康对照,验证集为40例早期PDAC与40例匹配健康对照。

主要发现

  • 比较甲基化组分析鉴定出9个在位点在外分泌胰腺DNA中差异甲基化。
  • 在训练集(n=124例患者)中,cfDNA甲基化标志物可区分PDAC与健康和CRC对照。
  • 在测试集86例早期PDAC与86例匹配健康对照中,CA19-9的AUC为0.88(95%CI 0.83-0.94),加入TIMP1后AUC为0.92(95%CI 0.88-0.96;p=0.06),加入LRG1后AUC为0.92(95%CI 0.88-0.96;p=0.02),加入9位点外分泌胰腺特异性cfDNA甲基化标志物后AUC为0.92(95%CI 0.88-0.96;p=0.02)。
  • 在验证集40例早期PDAC与40例匹配健康对照中,包含CA19-9、TIMP1和9位点cfDNA甲基化面板的组合面板鉴别能力(AUC 0.86,95%CI 0.77-0.95)高于CA19-9单用(AUC 0.82;95%CI 0.72-0.92)。

关键数值与推荐

  • 测试集:CA19-9的AUC为0.88(95%CI 0.83-0.94),加入TIMP1后AUC 0.92(95%CI 0.88-0.96;p=0.06),加入LRG1后AUC 0.92(95%CI 0.88-0.96;p=0.02),加入9位点cfDNA甲基化标志物后AUC 0.92(95%CI 0.88-0.96;p=0.02)。
  • 验证集:CA19-9+TIMP1+9位点cfDNA甲基化组合面板AUC 0.86(95%CI 0.77-0.95),CA19-9单用AUC 0.82(95%CI 0.72-0.92)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC when curative treatments can be employed. DESIGN: To assess circulating marker discrimination in training, testing and validation patient cohorts (total n=426 patients), plasma markers were measured among PDAC cases and patients with chronic pancreatitis, colorectal cancer (CRC), and healthy controls. Using CA19-9 as an anchor marker, measurements were made of two protein markers (TIMP1, LRG1) and cell-free DNA (cfDNA) pancreas-specific methylation at 9 loci encompassing 61 CpG sites. RESULTS: Comparative methylome analysis identified nine loci that were differentially methylated in exocrine pancreas DNA. In the training set (n=124 patients), cfDNA methylation markers distinguished PDAC from healthy and CRC controls. In the testing set of 86 early stage PDAC and 86 matched healthy controls, CA19-9 had an area under the receiver operating characteristic curve (AUC) of 0.88 (95% CI 0.83 to 0.94), which was increased by adding TIMP1 (AUC 0.92; 95% CI 0.88 to 0.96; p=0.06), LRG1 (AUC 0.92; 95% CI 0.88 to 0.96; p=0.02) or exocrine pancreas-specific cfDNA methylation markers at nine loci (AUC 0.92; 95% CI 0.88 to 0.96; p=0.02). In the validation set of 40 early stage PDAC and 40 matched healthy controls, a combined panel including CA19-9, TIMP1 and a 9-loci cfDNA methylation panel had greater discrimination (AUC 0.86, 95% CI 0.77 to 0.95) than CA19-9 alone (AUC 0.82; 95% CI 0.72 to 0.92). CONCLUSION: A combined panel of circulating markers including proteins and methylated cfDNA increased discrimination compared with CA19-9 alone for early stage PDAC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ben-Ami R, Wang QL, Zhang J, et al. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024. PMID: 38123998. doi:10.1136/gutjnl-2023-331074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。